AbbVie news
The WiseView Research desk's stories that name AbbVie, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The ABBV page →
- HeadlineThe Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18
- HeadlineRetire on Dividends: 5 High-Yield Stocks Boomers Are Buying and Holding Forever
- Headline4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential
- HeadlineBuy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings
- HeadlineAbbVie: Analyzing Performance, Pipeline, And Pricing Ahead Of Q3 (Strong Buy)
- HeadlineWhat's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?
- HeadlineAllergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA)
- HeadlineAbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma
- HeadlineAbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30
- HeadlineBest Dividend Kings: October 2026
- Week aheadWeek Ahead: Fed Decision, GDP, PCE Inflation and Peak Earnings Week
The Fed's rate decision, Q3 GDP and core PCE inflation headline a week in which 178 S&P 500 companies report earnings.
- HeadlineA Worthwhile Exit Strategy
- HeadlineU.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease
- HeadlineAbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?
- HeadlineForget Chasing 7% Yields: These 5 Dividend Stocks Offer Something Different
- HeadlineThe Dividend Aristocrats Ranked By Quality Scores (October 2026)
- HeadlineAbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- HeadlineWhat Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer
- HeadlineGreat News for AbbVie Stock Investors
- HeadlineAbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True?
- HeadlineAbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
- HeadlineAbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa
- HeadlineAbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
- HeadlineAbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?
- HeadlineForget Social Security: 5 High-Yield Stocks Retirees Are Buying Instead
- HeadlineAllergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence
- HeadlineAbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
- HeadlineAbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community
- HeadlineAbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results
- HeadlineAbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease
- HeadlineAbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
- HeadlineAbbVie's Dividend Keeps Climbing. Is It Still a Buy for Income Investors?
- HeadlineForget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle
- HeadlineHere's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends
- HeadlineAbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
- HeadlineAbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
- HeadlineBlockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying
- Headline5 High-Yield Dividend Stocks That Could Turn October's Market Weakness Into Income
- HeadlineAbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
- HeadlineAbbVie (ABBV) Rises As Market Takes a Dip: Key Facts
- HeadlineBiotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
- HeadlineWill Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3?
- HeadlinePrediction: AbbVie's Next Billion-Dollar Opportunity Is Taking Shape
- Headline5 Dividend Stocks for Retirees Who Want More Than Just a Big Yield
- CongressRo Khanna sold $15,001 - $50,000 of ABBV
- HeadlineCantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks
- HeadlineAbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
- HeadlineAI ETFs: Beyond Chips & Hyperscalers
- Headline5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong
- HeadlineAbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
- HeadlineAbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL
- HeadlineWall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?
- CongressPete Sessions sold $15,001 - $50,000 of ABBV
- CongressRo Khanna bought $15,001 - $50,000 of ABBV
- CongressJosh Gottheimer sold $1,001 - $15,000 of ABBV
- CongressJulie Johnson sold $1,001 - $15,000 of ABBV
- CongressJulia Letlow sold $1,001 - $15,000 of ABBV
- CongressJulia Letlow bought $1,001 - $15,000 of ABBV
- CongressJulia Letlow sold $1,001 - $15,000 of ABBV
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.